GLP-1-(9–36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion
- 1 April 2002
- journal article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 282 (4), E873-E879
- https://doi.org/10.1152/ajpendo.00452.2001
Abstract
Glucagon-like peptide 1 (GLP-1) is a potent anti-hyperglycemic hormone currently under investigation for its therapeutic potential. However, due to rapid degradation by dipeptidyl peptidase IV (DPP IV), which limits its metabolic stability and eliminates its insulinotropic activity, it has been impossible to assess its true efficacy in vivo. In chloralose-anesthetized pigs given valine-pyrrolidide (to block endogenous DPP IV activity), the independent effects of GLP-1-(7–36) amide on glucose and insulin responses to intravenous glucose were assessed, and the metabolite generated by DPP IV, GLP-1-(9–36) amide, was investigated for any ability to influence these responses. GLP-1-(7–36) amide enhanced insulin secretion ( P < 0.03 vs. vehicle), but GLP-1-(9–36) amide was without effect, either alone or when coinfused with GLP-1-(7–36) amide. In contrast, GLP-1-(9–36) amide did affect glucose responses ( P < 0.03). Glucose excursions were greater after saline (121 ± 17 mmol · l−1· min) than after GLP-1-(9–36) amide (73 ± 19 mmol · l−1· min; P < 0.05), GLP-1-(7–36) amide (62 ± 13 mmol · l−1· min; P < 0.02) or GLP-1-(7–36) amide + GLP-1-(9–36) amide (50 ± 13 mmol · l−1· min; P < 0.005). Glucose elimination rates were faster after GLP-1-(7–36) amide + (9–36) amide (10.3 ± 1.2%/min) than after GLP-1-(7–36) amide (7.0 ± 0.9%/min; P < 0.04), GLP-1-(9–36) amide (6.8 ± 1.0%/min; P < 0.03), or saline (5.4 ± 1.2%/min; P < 0.005). Glucagon concentrations were unaffected. These results demonstrate that GLP-1-(9–36) amide neither stimulates insulin secretion nor antagonizes the insulinotropic effect of GLP-1-(7–36) amide in vivo. Moreover, the metabolite itself possesses anti-hyperglycemic effects, supporting the hypothesis that selective DPP IV action is important in glucose homeostasis.Keywords
This publication has 35 references indexed in Scilit:
- Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.JCI Insight, 1998
- GLP-1 (7 - 36) Amide: Effects on Glucose Transport and Metabolism in Rat Adipose TissueHormone and Metabolic Research, 1997
- Bovine Aortic Endothelial Cells Contain an Angiotensin-(1–7) ReceptorHypertension, 1997
- Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptorEuropean Journal of Pharmacology, 1996
- Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal TabletDiabetes Care, 1996
- Glucagon‐like peptide 1: A potent glycogenic hormoneFEBS Letters, 1994
- Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.JCI Insight, 1994
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumJBIC Journal of Biological Inorganic Chemistry, 1993
- Novel generation of hormone receptor specificity by amino terminal processing of peptide YYBiochemical and Biophysical Research Communications, 1992
- Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.JCI Insight, 1991